Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5019 - Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Cytotoxic Therapy

Tumour Site

Ovarian Cancer

Presenters

Amit Oza

Citation

Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285

Authors

A.M. Oza1, D. Cibula2, A. Oaknin3, C. Poole4, R.H.J. Mathijssen5, G.S. Sonke6, N. Colombo7, J. Špaček8, P. Vuylsteke9, H. Hirte10, J. Pfisterer11, M. Plante12, L.C. Hanker13, A. Fielding14, V. Haddad15, J. Chmielecki16, M. Friedlander17

Author affiliations

  • 1 Medical Oncology And Hematology, Princess Margaret Cancer Center, M5G 2M9 - Toronto/CA
  • 2 Department Of Gynaecology And Obstetrics, General University Hospital, Prague/CZ
  • 3 Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 4 Medical Oncology, University Hospitals Coventry and Warwickshire NHS Trust, CV2 2DX - Coventry/GB
  • 5 Department Of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam/NL
  • 6 Department Of Medical Oncology, The Netherlands Cancer Institute, 1066 CX - Amsterdam/NL
  • 7 Gynecologic Oncology, University of Milan-Bicocca and Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 8 Department Of Obstetrics And Gynecology, University Hospital, Hradec Kralove/CZ
  • 9 Oncologie Médicale, CHU UCL Namur, Ste Elisabeth, 5000 - Namur/BE
  • 10 Department Of Oncology, Juravinski Cancer Centre, L8V 5C2 - Hamilton/CA
  • 11 Ago Study Group, Center of Gynecological Oncology, 24103 - Kiel/DE
  • 12 Gynecologic Oncology Division, Laval University, Quebec City/CA
  • 13 Department Of Gynaecology And Obstetrics, University of Lübeck, 23562 - Lübeck/DE
  • 14 Medical Science, Astrazeneca, Cambridge/GB
  • 15 Statistical Science, AstraZeneca UK, Cambridge/GB
  • 16 Translational Science, Oncology, Imed Biotech Unit, AstraZeneca, Waltham/US
  • 17 Medical Oncology, University of New South Wales Clinical School, Prince of Wales Hospital, 2031 - Randwick/AU
More

Resources

Abstract 5019

Background

The PARP inhibitor olaparib (Lynparza®) is approved as maintenance therapy in pts with PSR OC who are in complete or partial response to platinum-based chemotherapy. Currently, pts with SD are observed until disease progression; the efficacy of maintenance olaparib in these pts is unknown. In a Phase II study (NCT01081951), progression-free survival (PFS) was significantly prolonged in pts with PSR OC receiving olaparib plus platinum-based chemotherapy followed by maintenance olaparib vs those receiving platinum-based chemotherapy alone (Oza et al. Lancet Oncol 2015). This post hoc analysis evaluated outcomes in pts with SD on scans at the end of chemotherapy and the efficacy of maintenance olaparib vs observation.

Methods

In this open-label, multicentre trial, pts with PSR serous OC, primary peritoneal cancer or fallopian tube cancer were randomized to olaparib capsules 200 mg twice daily (bid) on days 1–10 of each 21-day cycle plus paclitaxel and carboplatin AUC 4 on day 1 (n = 81) followed by maintenance olaparib 400 mg bid (continuously), or paclitaxel and carboplatin AUC 6 on day 1 (n = 81) without maintenance olaparib. The latest scan from randomization up to 2 weeks after the final dose of carboplatin was used to assess the best objective RECIST v1.1 response at the end of chemotherapy (blinded independent central review).

Results

At the end of chemotherapy, 24 (29.6%) pts who had also received low-dose olaparib and 21 (25.9%) pts without olaparib had SD as their best response (timing of the scan ranged from 2.10 months before to 0.49 months after the last dose of carboplatin). Median PFS, calculated from the end of chemotherapy, was 8.74 months with maintenance olaparib at standard dose vs 5.40 months without maintenance olaparib (hazard ratio 0.50; 95% CI 0.25, 1.00). Delayed responses following the end of chemotherapy occurred in four pts receiving maintenance olaparib (16.7%; two complete and two partial responses) and three pts without maintenance olaparib (14.3%; all partial responses). The number of lines of prior chemotherapy did not appear predictive of PFS benefit.

Conclusions

Maintenance olaparib may prolong PFS in OC pts with SD following platinum-based therapy.

Clinical trial identification

NCT01081951.

Legal entity responsible for the study

AstraZeneca.

Funding

AstraZeneca.

Editorial Acknowledgement

Editorial assistance was provided by Gillian Keating, Mudskipper Business Limited, funded by AstraZeneca.

Disclosure

A.M. Oza: Honoraria: Intas Pharma. D. Cibula: Fees for advisory boards: Roche, AstraZeneca. A. Oaknin: Fees for advisory boards: Roche, AstraZeneca, PharmaMar, Clovis Oncology, Tesaro; Support for travel/accommodation: Roche, AstraZeneca, PharmaMar. C. Poole: Honoraria for advisory boards: Pfizer, AstraZeneca, Genomic Health, Lilly; Honoraria for talks: Pfizer, AstraZeneca, Genomic Health; Consultancy fees: Creavo Medical Technologies. R.H.J. Mathijssen: Research funding: Astellas, Bayer, Boehringer Ingelheim, Cristal Therapeutics, Novartis, Pamgene, Pfizer, Roche, Sanofi; Consultation fees: Novartis, Servier; Travel support: Astellas, Pfizer. G.S. Sonke: Research funding: AstraZeneca, Merck, Novartis, Roche. N. Colombo: Honoraria: Genentech, AstraZeneca, PharmaMar; Fees for consulting/advisory boards: Genentech, PharmaMar, AstraZeneca, Clovis Oncology, Pfizer, MSD, Tesaro; Research funding: AstraZeneca. P. Vuylsteke: Fees for advisory boards: AstraZeneca, Roche, Eli Lilly. H. Hirte: Honoraria for advisory boards: AstraZeneca, Roche. J. Pfisterer, L.C. Hanker: Fees for advisory boards: Roche, AstraZeneca, Tesaro. M. Plante: Support for travel/accommodation: AstraZeneca. A. Fielding, V. Haddad, J. Chmielecki: Employee of AstraZeneca. M. Friedlander: Fees for advisory boards: AstraZeneca, MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.